Trial Outcomes & Findings for Pain Relief With Integrative Medicine (PRIMe)?: Feasibility of Acupuncture for Long COVID (NCT NCT06476496)

NCT ID: NCT06476496

Last Updated: 2026-05-12

Results Overview

The PEG is a widely used brief, three-item instrument that measures average pain intensity, enjoyment of life, and general activity in the past week, each rated on a 0 to 10 scale. Scores are calculated by averaging the scores of each of the three items. A higher score indicates worse pain impact.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

93 participants

Primary outcome timeframe

Baseline (Week 0), Mid-Point (Week 4), Post-Intervention (Week 8), and Final Follow-Up (Week 20)

Results posted on

2026-05-12

Participant Flow

Individuals were recruited through the UW Long COVID Clinic. Those who opted in with the clinic to be contacted for research opportunities received an email describing the study and a link to the screener to determine eligibility. Recruitment was open for 2-3 weeks before the acupuncture sessions began until all open acupuncture spots were filled.

Participant milestones

Participant milestones
Measure
Acupuncture
Participants in the Acupuncture group were asked to attend 8 weekly acupuncture sessions. Each session took place at a central primary care clinic. The visits lasted 1 hour and included a brief assessment, needle insertion at selected body and ear acupoints while the participant lay supine. After removing the needles, up to 10 Pyonex press tags (shallow needles) were applied to specific points, and participants were instructed to keep them in place for at least 3 days.
Usual Care
Participants in the usual care group did not receive any additional treatment from the study.
Overall Study
STARTED
46
47
Overall Study
COMPLETED
35
46
Overall Study
NOT COMPLETED
11
1

Reasons for withdrawal

Reasons for withdrawal
Measure
Acupuncture
Participants in the Acupuncture group were asked to attend 8 weekly acupuncture sessions. Each session took place at a central primary care clinic. The visits lasted 1 hour and included a brief assessment, needle insertion at selected body and ear acupoints while the participant lay supine. After removing the needles, up to 10 Pyonex press tags (shallow needles) were applied to specific points, and participants were instructed to keep them in place for at least 3 days.
Usual Care
Participants in the usual care group did not receive any additional treatment from the study.
Overall Study
Withdrawal by Subject
10
0
Overall Study
Death
0
1
Overall Study
Withdrawal by Study Team
1
0

Baseline Characteristics

All participates reported age

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Acupuncture
n=46 Participants
Participants in the Acupuncture group were asked to attend 8 weekly acupuncture sessions. Each session took place at a central primary care clinic. The visits lasted 1 hour and included a brief assessment, needle insertion at selected body and ear acupoints while the participant lay supine. After removing the needles, up to 10 Pyonex press tags (shallow needles) were applied to specific points, and participants were instructed to keep them in place for at least 3 days.
Usual Care
n=47 Participants
Participants in the usual care group did not receive any additional treatment as part of the study. They were instructed to continue receiving any care recommended to them by their PCP or Long COVID Clinician.
Total
n=93 Participants
Total of all reporting groups
Age, Continuous
45.15 years
STANDARD_DEVIATION 12.25 • n=1512 Participants • All participates reported age
46.47 years
STANDARD_DEVIATION 12.67 • n=504 Participants • All participates reported age
45.82 years
STANDARD_DEVIATION 12.41 • n=2016 Participants • All participates reported age
Sex/Gender, Customized
Female
34 Participants
n=1512 Participants
35 Participants
n=504 Participants
69 Participants
n=2016 Participants
Sex/Gender, Customized
Male
12 Participants
n=1512 Participants
11 Participants
n=504 Participants
23 Participants
n=2016 Participants
Sex/Gender, Customized
Prefer Not to Answer
0 Participants
n=1512 Participants
1 Participants
n=504 Participants
1 Participants
n=2016 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=1512 Participants
1 Participants
n=504 Participants
1 Participants
n=2016 Participants
Race (NIH/OMB)
Asian
3 Participants
n=1512 Participants
5 Participants
n=504 Participants
8 Participants
n=2016 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=1512 Participants
0 Participants
n=504 Participants
0 Participants
n=2016 Participants
Race (NIH/OMB)
Black or African American
3 Participants
n=1512 Participants
2 Participants
n=504 Participants
5 Participants
n=2016 Participants
Race (NIH/OMB)
White
33 Participants
n=1512 Participants
29 Participants
n=504 Participants
62 Participants
n=2016 Participants
Race (NIH/OMB)
More than one race
2 Participants
n=1512 Participants
2 Participants
n=504 Participants
4 Participants
n=2016 Participants
Race (NIH/OMB)
Unknown or Not Reported
5 Participants
n=1512 Participants
8 Participants
n=504 Participants
13 Participants
n=2016 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
2 Participants
n=1512 Participants
8 Participants
n=504 Participants
10 Participants
n=2016 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
42 Participants
n=1512 Participants
36 Participants
n=504 Participants
78 Participants
n=2016 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
2 Participants
n=1512 Participants
3 Participants
n=504 Participants
5 Participants
n=2016 Participants

PRIMARY outcome

Timeframe: Baseline (Week 0), Mid-Point (Week 4), Post-Intervention (Week 8), and Final Follow-Up (Week 20)

Population: The number of participants analyzed is determined by the number of participants who completed the primary outcome measure survey.

The PEG is a widely used brief, three-item instrument that measures average pain intensity, enjoyment of life, and general activity in the past week, each rated on a 0 to 10 scale. Scores are calculated by averaging the scores of each of the three items. A higher score indicates worse pain impact.

Outcome measures

Outcome measures
Measure
Acupuncture
n=46 Participants
Participants in the Acupuncture group were asked to attend 8 weekly acupuncture sessions. Each session took place at a central primary care clinic. The visits lasted 1 hour and included a brief assessment, needle insertion at selected body and ear acupoints while the participant lay supine. After removing the needles, up to 10 Pyonex press tags (shallow needles) were applied to specific points, and participants were instructed to keep them in place for at least 3 days.
Usual Care
n=47 Participants
Participants in the usual care group did not receive any additional treatment as part of the study. They were instructed to continue receiving any care recommended to them by their PCP or Long COVID Clinician.
Pain, Enjoyment and General Activity (PEG)
Post-Intervention (Week 8)
4.95 Score
Standard Deviation 2.14
6.03 Score
Standard Deviation 2.11
Pain, Enjoyment and General Activity (PEG)
Baseline (Week 0)
6.74 Score
Standard Deviation 1.43
6.74 Score
Standard Deviation 1.51
Pain, Enjoyment and General Activity (PEG)
Midpoint (Week 4)
8.33 Score
Standard Deviation 2.08
9.33 Score
Standard Deviation 1.91
Pain, Enjoyment and General Activity (PEG)
Final Follow-Up (Week 20)
4.77 Score
Standard Deviation 2.22
5.89 Score
Standard Deviation 1.97

SECONDARY outcome

Timeframe: Baseline (Week 0), Post-Intervention (Week 8) and Final Follow-Up (Week 20)

Population: The number analyzed is determined by the number of participants who completed each survey time point.

The Pain Catastrophizing Scale (PCS) - Short Form is a 6-item self-report measure of catastrophic thinking related to pain, including rumination, magnification, and helplessness. PCS is a commonly used measure of pain experience and catastrophizing. Each measure is scored on a scale of 0 to 4. The PCS-SF score is determined by the sum of all 6 items; scores range from 0 to 24. Higher scores indicate greater catastrophizing.

Outcome measures

Outcome measures
Measure
Acupuncture
n=46 Participants
Participants in the Acupuncture group were asked to attend 8 weekly acupuncture sessions. Each session took place at a central primary care clinic. The visits lasted 1 hour and included a brief assessment, needle insertion at selected body and ear acupoints while the participant lay supine. After removing the needles, up to 10 Pyonex press tags (shallow needles) were applied to specific points, and participants were instructed to keep them in place for at least 3 days.
Usual Care
n=47 Participants
Participants in the usual care group did not receive any additional treatment as part of the study. They were instructed to continue receiving any care recommended to them by their PCP or Long COVID Clinician.
Pain Catastrophizing Scale (PCS) Short Form
Baseline (Week 0)
12.37 Score
Standard Deviation 5.91
12.62 Score
Standard Deviation 5.38
Pain Catastrophizing Scale (PCS) Short Form
Final Follow-Up (Week 20)
7.52 Score
Standard Deviation 5.91
11.97 Score
Standard Deviation 5.45
Pain Catastrophizing Scale (PCS) Short Form
Post-Intervention (Week 8)
9.48 Score
Standard Deviation 5.81
11.68 Score
Standard Deviation 5.96

SECONDARY outcome

Timeframe: Baseline (Week 0), Post-Intervention (Week 8), and Final Follow-up (Week 20)

Population: The number of participants reported for each arm and time point reflects the number of completed survey responses.

PROMIS® (Patient-Reported Outcomes Measurement Information System) is a collection of person-centered tools that assess and track physical, mental, and social health in both adults and children. The PROMIS-29 Questionnaire includes 4-item short forms that measure anxiety, depression, fatigue, pain interference, physical function, sleep disturbance, and social role participation, along with a single item for pain intensity. Raw scores were converted to T-scores (using an adult referent population), ranging from 0 to 100, with a mean of 50 and a standard deviation (SD) of 10 in the reference population. High scores indicate more of the concept being measured (e.g., for physical function and ability to participate in social activities, a higher score signifies greater function; for all other domains, a higher score indicates worse function). Pain intensity is a single item scored separately on a scale of 0 to 10, with higher scores representing worse pain.

Outcome measures

Outcome measures
Measure
Acupuncture
n=46 Participants
Participants in the Acupuncture group were asked to attend 8 weekly acupuncture sessions. Each session took place at a central primary care clinic. The visits lasted 1 hour and included a brief assessment, needle insertion at selected body and ear acupoints while the participant lay supine. After removing the needles, up to 10 Pyonex press tags (shallow needles) were applied to specific points, and participants were instructed to keep them in place for at least 3 days.
Usual Care
n=47 Participants
Participants in the usual care group did not receive any additional treatment as part of the study. They were instructed to continue receiving any care recommended to them by their PCP or Long COVID Clinician.
PROMIS-29
Ability to Participate in Social Roles: Baseline (Week 0)
37.44 Scores
Standard Deviation 6.44
37.62 Scores
Standard Deviation 7.86
PROMIS-29
Ability to Participate in Social Roles: Post Intervention (Week 8)
38.95 Scores
Standard Deviation 6.7
37.03 Scores
Standard Deviation 8.23
PROMIS-29
Ability to Participate in Social Roles: Final Follow-Up (Week 20)
40.39 Scores
Standard Deviation 7.4
37.97 Scores
Standard Deviation 7.66
PROMIS-29
Anxiety/Fear: Baseline (Week 0)
60.47 Scores
Standard Deviation 10.31
59.78 Scores
Standard Deviation 9.99
PROMIS-29
Anxiety/Fear: Post Intervention (Week 8)
60.3 Scores
Standard Deviation 9.02
61.56 Scores
Standard Deviation 8.11
PROMIS-29
Anxiety/Fear: Final Follow-Up (Week 20)
60.95 Scores
Standard Deviation 12.16
61.29 Scores
Standard Deviation 8.04
PROMIS-29
Depression/Sadness: Baseline (Week 0)
58.84 Scores
Standard Deviation 9.42
57.78 Scores
Standard Deviation 10.14
PROMIS-29
Depression/Sadness: Post Intervention (Week 8)
58.3 Scores
Standard Deviation 9.56
58.62 Scores
Standard Deviation 9.48
PROMIS-29
Depression/Sadness: Final Follow-Up (Week 20)
58.89 Scores
Standard Deviation 9.7
58.41 Scores
Standard Deviation 10.15
PROMIS-29
Fatigue: Baseline (Week 0)
68.92 Scores
Standard Deviation 6.72
68.26 Scores
Standard Deviation 7.91
PROMIS-29
Fatigue: Post Intervention (Week 8)
66.06 Scores
Standard Deviation 7.6
69.22 Scores
Standard Deviation 8.15
PROMIS-29
Fatigue: Final Follow-Up (Week 20)
66.04 Scores
Standard Deviation 8.42
66.1 Scores
Standard Deviation 8.74
PROMIS-29
Pain Interference: Baseline (Week 0)
65.69 Scores
Standard Deviation 5.18
65.18 Scores
Standard Deviation 6.13
PROMIS-29
Pain Interference: Post Intervention (Week 8)
61.11 Scores
Standard Deviation 8.3
64.51 Scores
Standard Deviation 6.95
PROMIS-29
Pain Interference: Final Follow-Up (Week 20)
62.62 Scores
Standard Deviation 6.94
65.11 Scores
Standard Deviation 6.26
PROMIS-29
Physical Function: Baseline (Week 0)
36.79 Scores
Standard Deviation 5.66
36.74 Scores
Standard Deviation 6.77
PROMIS-29
Physical Function: Post Intervention (Week 8)
38.81 Scores
Standard Deviation 6.03
37 Scores
Standard Deviation 7.94
PROMIS-29
Physical Function: Final Follow-Up (Week 20)
59.06 Scores
Standard Deviation 8.2
57.27 Scores
Standard Deviation 7.05
PROMIS-29
Sleep Disturbance: Baseline (Week 0)
59.05 Scores
Standard Deviation 7.48
59.66 Scores
Standard Deviation 7.22
PROMIS-29
Sleep Disturbance: Post Intervention (Week 8)
56.62 Scores
Standard Deviation 6.98
59.52 Scores
Standard Deviation 6.88
PROMIS-29
Sleep Disturbance: Final Follow-Up (Week 20)
59.06 Scores
Standard Deviation 8.2
57.27 Scores
Standard Deviation 7.05
PROMIS-29
Pain Intensity: Baseline (Week 0)
6.22 Scores
Standard Deviation 1.26
6.38 Scores
Standard Deviation 1.44
PROMIS-29
Pain Intensity: Post Intervention (Week 8)
4.81 Scores
Standard Deviation 1.99
6.05 Scores
Standard Deviation 1.92
PROMIS-29
Pain Intensity: Final Follow-Up (Week 20)
4.9 Scores
Standard Deviation 2.2
6.2 Scores
Standard Deviation 1.83

SECONDARY outcome

Timeframe: Baseline (Week 0), Post-Intervention (Week 8), and Final Follow-Up (Week 20)

Population: The number analyzed is determined by the number of participants who completed each survey time point.

The PROMIS Cognitive Function scale complements the PROMIS-29 with questions relevant to participants with Long COVID comorbidities, such as "brain fog." This scale measures patient-perceived cognitive deficits. Aspects include mental clarity, focus, verbal and nonverbal memory, verbal fluency, and perceived changes in cognitive functions. The scale consists of 8 items, each rated from 1 to 5 to generate a raw score; all 8 items must be answered for the scale to be scored. The T-score converts the raw score into a standardized score with a mean of 50 and a standard deviation (SD) of 10. Therefore, a person with a T-score of 40 is one SD below the mean.

Outcome measures

Outcome measures
Measure
Acupuncture
n=46 Participants
Participants in the Acupuncture group were asked to attend 8 weekly acupuncture sessions. Each session took place at a central primary care clinic. The visits lasted 1 hour and included a brief assessment, needle insertion at selected body and ear acupoints while the participant lay supine. After removing the needles, up to 10 Pyonex press tags (shallow needles) were applied to specific points, and participants were instructed to keep them in place for at least 3 days.
Usual Care
n=47 Participants
Participants in the usual care group did not receive any additional treatment as part of the study. They were instructed to continue receiving any care recommended to them by their PCP or Long COVID Clinician.
PROMIS Cognitive Function
Baseline (Week 0)
33.52 Scores
Standard Deviation 8.97
31.56 Scores
Standard Deviation 8.36
PROMIS Cognitive Function
Post Intervention (Week 8)
35.62 Scores
Standard Deviation 10.05
33.04 Scores
Standard Deviation 8.25
PROMIS Cognitive Function
Final Follow-Up (Week 20)
37.87 Scores
Standard Deviation 10.48
32.92 Scores
Standard Deviation 8.44

SECONDARY outcome

Timeframe: Weeks 0, 8, 20

Population: The number analyzed is determined by the number of participants who completed each survey time point.

Pain-related self-efficacy is an individual's belief in their ability to accomplish important tasks and activities despite their pain. Identified subdomains include: Control/tolerance of/cope with symptoms, ability to manage the impact of pain on mood and psychological functioning, interpersonal relationships, and confidence to accomplish goals despite pain. The UW-PRSE was developed in a sample of adults living with chronic pain (mild to severe pain with average pain intensity of 3 or above on a scale from 0 to 10 for six months or longer and for at least half the days). This study used the 6-item short form. Individual items are summed, and the total sum is then transformed to an IRT-based T-score. T-Scores are standardized scores with a mean of 50 and a standard deviation (SD) of 10. The mean score of the calibration sample included only individuals with chronic pain. A higher T-Score indicates higher self-efficacy.

Outcome measures

Outcome measures
Measure
Acupuncture
n=46 Participants
Participants in the Acupuncture group were asked to attend 8 weekly acupuncture sessions. Each session took place at a central primary care clinic. The visits lasted 1 hour and included a brief assessment, needle insertion at selected body and ear acupoints while the participant lay supine. After removing the needles, up to 10 Pyonex press tags (shallow needles) were applied to specific points, and participants were instructed to keep them in place for at least 3 days.
Usual Care
n=47 Participants
Participants in the usual care group did not receive any additional treatment as part of the study. They were instructed to continue receiving any care recommended to them by their PCP or Long COVID Clinician.
UW Pain Related Self-Efficacy Scale (PRSE)
Baseline (Week 0)
44.24 T-Scores
Standard Deviation 7.25
43.71 T-Scores
Standard Deviation 8.02
UW Pain Related Self-Efficacy Scale (PRSE)
Post Intervention (Week 8)
47.75 T-Scores
Standard Deviation 7.88
45.23 T-Scores
Standard Deviation 10.89
UW Pain Related Self-Efficacy Scale (PRSE)
Final Follow-Up (Week 20)
44.9 T-Scores
Standard Deviation 10.06
44.98 T-Scores
Standard Deviation 9.24

OTHER_PRE_SPECIFIED outcome

Timeframe: Prior to enrollment

Timely recruitment of study participants (criteria: complete recruitment of 60 participants within five months);

Outcome measures

Outcome measures
Measure
Acupuncture
n=93 Participants
Participants in the Acupuncture group were asked to attend 8 weekly acupuncture sessions. Each session took place at a central primary care clinic. The visits lasted 1 hour and included a brief assessment, needle insertion at selected body and ear acupoints while the participant lay supine. After removing the needles, up to 10 Pyonex press tags (shallow needles) were applied to specific points, and participants were instructed to keep them in place for at least 3 days.
Usual Care
Participants in the usual care group did not receive any additional treatment as part of the study. They were instructed to continue receiving any care recommended to them by their PCP or Long COVID Clinician.
Total Time to Recruit All Study Participants
3 months

OTHER_PRE_SPECIFIED outcome

Timeframe: Weeks 1-8

Population: Only participants in the acupuncture arm are included in this measure. We had 11 participants withdraw from the study post-randomization and before their first acupuncture appointment - those individuals were not included in this measure analysis. The reason for withdrawal was primarily issues traveling to the acupuncture clinic (high traffic, too late, etc.)

Retention of participants in the treatment (criteria: 75% of participants attend at least 6 of 8 acupuncture visits)

Outcome measures

Outcome measures
Measure
Acupuncture
n=35 Participants
Participants in the Acupuncture group were asked to attend 8 weekly acupuncture sessions. Each session took place at a central primary care clinic. The visits lasted 1 hour and included a brief assessment, needle insertion at selected body and ear acupoints while the participant lay supine. After removing the needles, up to 10 Pyonex press tags (shallow needles) were applied to specific points, and participants were instructed to keep them in place for at least 3 days.
Usual Care
Participants in the usual care group did not receive any additional treatment as part of the study. They were instructed to continue receiving any care recommended to them by their PCP or Long COVID Clinician.
Study Participants' Retention in Treatment Arm
29 Participants

OTHER_PRE_SPECIFIED outcome

Timeframe: Weeks 0, 4, 8, 20

Population: We had 11 acupuncture participants withdraw from the study post-randomization and before their first acupuncture appointment - the denominator for the surveys are the number of still-active participants who received the survey. The reason for withdrawal was primarily issues traveling to the acupuncture clinic (high traffic, too late, etc.)

Questionnaire Response Rates: (criterion: 70% of participants complete baseline, mid-point, and post-treatment questionnaires; 75% complete final questionnaire) The baseline survey was required to complete enrollment.

Outcome measures

Outcome measures
Measure
Acupuncture
n=46 Participants
Participants in the Acupuncture group were asked to attend 8 weekly acupuncture sessions. Each session took place at a central primary care clinic. The visits lasted 1 hour and included a brief assessment, needle insertion at selected body and ear acupoints while the participant lay supine. After removing the needles, up to 10 Pyonex press tags (shallow needles) were applied to specific points, and participants were instructed to keep them in place for at least 3 days.
Usual Care
n=47 Participants
Participants in the usual care group did not receive any additional treatment as part of the study. They were instructed to continue receiving any care recommended to them by their PCP or Long COVID Clinician.
Survey Response Rates
Post-Intervention (Week 8)
31 Participants
38 Participants
Survey Response Rates
Final Follow-Up (Week 20)
31 Participants
35 Participants
Survey Response Rates
Baseline (Week 0)
46 Participants
47 Participants
Survey Response Rates
Midpoint (Week 4)
33 Participants
38 Participants

OTHER_PRE_SPECIFIED outcome

Timeframe: Weeks 1 - 8

Population: Only participants in the acupuncture arm are included in this measure. We had 11 participants withdraw from the study post-randomization and before their first acupuncture appointment - those individuals were not included in this measure analysis. The reason for withdrawal was primarily issues traveling to the acupuncture clinic (high traffic, too late, etc.)

Intervention fidelity (criteria: 80% of sessions fully adhere to the acupuncture treatment protocol). Each acupuncture visit was tracked, and a secondary acupuncturist provided quality control and reviewed the visit for fidelity to the acupuncture protocol.

Outcome measures

Outcome measures
Measure
Acupuncture
n=239 AcupunctureVisits
Participants in the Acupuncture group were asked to attend 8 weekly acupuncture sessions. Each session took place at a central primary care clinic. The visits lasted 1 hour and included a brief assessment, needle insertion at selected body and ear acupoints while the participant lay supine. After removing the needles, up to 10 Pyonex press tags (shallow needles) were applied to specific points, and participants were instructed to keep them in place for at least 3 days.
Usual Care
Participants in the usual care group did not receive any additional treatment as part of the study. They were instructed to continue receiving any care recommended to them by their PCP or Long COVID Clinician.
Adherance to the Treatment Protocol
228 Acupuncture Visits

OTHER_PRE_SPECIFIED outcome

Timeframe: Weeks 1-8

Population: Only participants in the acupuncture arm are included in this measure. We had 11 participants withdraw from the study post-randomization and before their first acupuncture appointment - those individuals were not included in this measure analysis. The reason for withdrawal was primarily issues traveling to the acupuncture clinic (high traffic, too late, etc.) Not all visits used the Pyonex press needles, so the number of visits these applied to is different than the total number of visits

Participant Adherence to treatment recommendations (criteria: 50% leave acupuncture needles in place for at least 3 days)

Outcome measures

Outcome measures
Measure
Acupuncture
n=204 Visits
Participants in the Acupuncture group were asked to attend 8 weekly acupuncture sessions. Each session took place at a central primary care clinic. The visits lasted 1 hour and included a brief assessment, needle insertion at selected body and ear acupoints while the participant lay supine. After removing the needles, up to 10 Pyonex press tags (shallow needles) were applied to specific points, and participants were instructed to keep them in place for at least 3 days.
Usual Care
Participants in the usual care group did not receive any additional treatment as part of the study. They were instructed to continue receiving any care recommended to them by their PCP or Long COVID Clinician.
Number of Visits Where Participants Adhered to Treatment Recommendations
202 AcupunctureVisits

Adverse Events

Usual Care

Serious events: 11 serious events
Other events: 0 other events
Deaths: 1 deaths

Acupuncture

Serious events: 10 serious events
Other events: 9 other events
Deaths: 1 deaths

Serious adverse events

Serious adverse events
Measure
Usual Care
n=47 participants at risk
Participants in the usual care group did not receive any additional treatment as part of the study. They were instructed to continue receiving any care recommended to them by their PCP or Long COVID Clinician.
Acupuncture
n=46 participants at risk
Participants in the Acupuncture group were asked to attend 8 weekly acupuncture sessions. Each session took place at a central primary care clinic. The visits lasted 1 hour and included a brief assessment, needle insertion at selected body and ear acupoints while the participant lay supine. After removing the needles, up to 10 Pyonex press tags (shallow needles) were applied to specific points, and participants were instructed to keep them in place for at least 3 days.
Gastrointestinal disorders
Abdominal pain
4.3%
2/47 • Number of events 3 • From enrollment until the end of follow-up (week 20)
For this study, a serious adverse event was anything requiring hospitalization, an ED visit, or death. None of the SAEs were related to the study. Adverse events included bruising or localized pain at the needle site.
0.00%
0/46 • From enrollment until the end of follow-up (week 20)
For this study, a serious adverse event was anything requiring hospitalization, an ED visit, or death. None of the SAEs were related to the study. Adverse events included bruising or localized pain at the needle site.
Injury, poisoning and procedural complications
Accidental injury (fracture or foreign body)
4.3%
2/47 • Number of events 2 • From enrollment until the end of follow-up (week 20)
For this study, a serious adverse event was anything requiring hospitalization, an ED visit, or death. None of the SAEs were related to the study. Adverse events included bruising or localized pain at the needle site.
0.00%
0/46 • From enrollment until the end of follow-up (week 20)
For this study, a serious adverse event was anything requiring hospitalization, an ED visit, or death. None of the SAEs were related to the study. Adverse events included bruising or localized pain at the needle site.
Immune system disorders
Allergic reaction
2.1%
1/47 • Number of events 1 • From enrollment until the end of follow-up (week 20)
For this study, a serious adverse event was anything requiring hospitalization, an ED visit, or death. None of the SAEs were related to the study. Adverse events included bruising or localized pain at the needle site.
0.00%
0/46 • From enrollment until the end of follow-up (week 20)
For this study, a serious adverse event was anything requiring hospitalization, an ED visit, or death. None of the SAEs were related to the study. Adverse events included bruising or localized pain at the needle site.
Cardiac disorders
Cardiac symptoms (palpitations or chest pain)
2.1%
1/47 • Number of events 1 • From enrollment until the end of follow-up (week 20)
For this study, a serious adverse event was anything requiring hospitalization, an ED visit, or death. None of the SAEs were related to the study. Adverse events included bruising or localized pain at the needle site.
2.2%
1/46 • Number of events 2 • From enrollment until the end of follow-up (week 20)
For this study, a serious adverse event was anything requiring hospitalization, an ED visit, or death. None of the SAEs were related to the study. Adverse events included bruising or localized pain at the needle site.
Eye disorders
Eye disorder (acute vision loss)
0.00%
0/47 • From enrollment until the end of follow-up (week 20)
For this study, a serious adverse event was anything requiring hospitalization, an ED visit, or death. None of the SAEs were related to the study. Adverse events included bruising or localized pain at the needle site.
2.2%
1/46 • Number of events 1 • From enrollment until the end of follow-up (week 20)
For this study, a serious adverse event was anything requiring hospitalization, an ED visit, or death. None of the SAEs were related to the study. Adverse events included bruising or localized pain at the needle site.
General disorders
General symptoms requiring evaluation
0.00%
0/47 • From enrollment until the end of follow-up (week 20)
For this study, a serious adverse event was anything requiring hospitalization, an ED visit, or death. None of the SAEs were related to the study. Adverse events included bruising or localized pain at the needle site.
2.2%
1/46 • Number of events 1 • From enrollment until the end of follow-up (week 20)
For this study, a serious adverse event was anything requiring hospitalization, an ED visit, or death. None of the SAEs were related to the study. Adverse events included bruising or localized pain at the needle site.
Renal and urinary disorders
Genitourinary or gynecologic symptoms
2.1%
1/47 • Number of events 1 • From enrollment until the end of follow-up (week 20)
For this study, a serious adverse event was anything requiring hospitalization, an ED visit, or death. None of the SAEs were related to the study. Adverse events included bruising or localized pain at the needle site.
2.2%
1/46 • Number of events 1 • From enrollment until the end of follow-up (week 20)
For this study, a serious adverse event was anything requiring hospitalization, an ED visit, or death. None of the SAEs were related to the study. Adverse events included bruising or localized pain at the needle site.
Reproductive system and breast disorders
Genitourinary or gynecologic symptoms
0.00%
0/47 • From enrollment until the end of follow-up (week 20)
For this study, a serious adverse event was anything requiring hospitalization, an ED visit, or death. None of the SAEs were related to the study. Adverse events included bruising or localized pain at the needle site.
2.2%
1/46 • Number of events 1 • From enrollment until the end of follow-up (week 20)
For this study, a serious adverse event was anything requiring hospitalization, an ED visit, or death. None of the SAEs were related to the study. Adverse events included bruising or localized pain at the needle site.
Infections and infestations
Infection (COVID-19 or influenza)
2.1%
1/47 • Number of events 1 • From enrollment until the end of follow-up (week 20)
For this study, a serious adverse event was anything requiring hospitalization, an ED visit, or death. None of the SAEs were related to the study. Adverse events included bruising or localized pain at the needle site.
2.2%
1/46 • Number of events 1 • From enrollment until the end of follow-up (week 20)
For this study, a serious adverse event was anything requiring hospitalization, an ED visit, or death. None of the SAEs were related to the study. Adverse events included bruising or localized pain at the needle site.
Musculoskeletal and connective tissue disorders
Musculoskeletal pain or injury
4.3%
2/47 • Number of events 2 • From enrollment until the end of follow-up (week 20)
For this study, a serious adverse event was anything requiring hospitalization, an ED visit, or death. None of the SAEs were related to the study. Adverse events included bruising or localized pain at the needle site.
6.5%
3/46 • Number of events 3 • From enrollment until the end of follow-up (week 20)
For this study, a serious adverse event was anything requiring hospitalization, an ED visit, or death. None of the SAEs were related to the study. Adverse events included bruising or localized pain at the needle site.
Nervous system disorders
Neurologic symptoms (dizziness)
0.00%
0/47 • From enrollment until the end of follow-up (week 20)
For this study, a serious adverse event was anything requiring hospitalization, an ED visit, or death. None of the SAEs were related to the study. Adverse events included bruising or localized pain at the needle site.
2.2%
1/46 • Number of events 1 • From enrollment until the end of follow-up (week 20)
For this study, a serious adverse event was anything requiring hospitalization, an ED visit, or death. None of the SAEs were related to the study. Adverse events included bruising or localized pain at the needle site.
Skin and subcutaneous tissue disorders
Peripheral swelling
2.1%
1/47 • Number of events 1 • From enrollment until the end of follow-up (week 20)
For this study, a serious adverse event was anything requiring hospitalization, an ED visit, or death. None of the SAEs were related to the study. Adverse events included bruising or localized pain at the needle site.
2.2%
1/46 • Number of events 1 • From enrollment until the end of follow-up (week 20)
For this study, a serious adverse event was anything requiring hospitalization, an ED visit, or death. None of the SAEs were related to the study. Adverse events included bruising or localized pain at the needle site.
Psychiatric disorders
Psychiatric disorders (psychosis)
0.00%
0/47 • From enrollment until the end of follow-up (week 20)
For this study, a serious adverse event was anything requiring hospitalization, an ED visit, or death. None of the SAEs were related to the study. Adverse events included bruising or localized pain at the needle site.
4.3%
2/46 • Number of events 2 • From enrollment until the end of follow-up (week 20)
For this study, a serious adverse event was anything requiring hospitalization, an ED visit, or death. None of the SAEs were related to the study. Adverse events included bruising or localized pain at the needle site.
Respiratory, thoracic and mediastinal disorders
Respiratory disorders (asthma exacerbation or epistaxis)
0.00%
0/47 • From enrollment until the end of follow-up (week 20)
For this study, a serious adverse event was anything requiring hospitalization, an ED visit, or death. None of the SAEs were related to the study. Adverse events included bruising or localized pain at the needle site.
2.2%
1/46 • Number of events 1 • From enrollment until the end of follow-up (week 20)
For this study, a serious adverse event was anything requiring hospitalization, an ED visit, or death. None of the SAEs were related to the study. Adverse events included bruising or localized pain at the needle site.
Surgical and medical procedures
Hospitalized for planned surgery
6.4%
3/47 • Number of events 3 • From enrollment until the end of follow-up (week 20)
For this study, a serious adverse event was anything requiring hospitalization, an ED visit, or death. None of the SAEs were related to the study. Adverse events included bruising or localized pain at the needle site.
2.2%
1/46 • Number of events 1 • From enrollment until the end of follow-up (week 20)
For this study, a serious adverse event was anything requiring hospitalization, an ED visit, or death. None of the SAEs were related to the study. Adverse events included bruising or localized pain at the needle site.
Infections and infestations
Urinary tract infection
0.00%
0/47 • From enrollment until the end of follow-up (week 20)
For this study, a serious adverse event was anything requiring hospitalization, an ED visit, or death. None of the SAEs were related to the study. Adverse events included bruising or localized pain at the needle site.
2.2%
1/46 • Number of events 1 • From enrollment until the end of follow-up (week 20)
For this study, a serious adverse event was anything requiring hospitalization, an ED visit, or death. None of the SAEs were related to the study. Adverse events included bruising or localized pain at the needle site.
Vascular disorders
Venous thromboembolism or suspected pulmonary embolism
2.1%
1/47 • Number of events 1 • From enrollment until the end of follow-up (week 20)
For this study, a serious adverse event was anything requiring hospitalization, an ED visit, or death. None of the SAEs were related to the study. Adverse events included bruising or localized pain at the needle site.
2.2%
1/46 • Number of events 1 • From enrollment until the end of follow-up (week 20)
For this study, a serious adverse event was anything requiring hospitalization, an ED visit, or death. None of the SAEs were related to the study. Adverse events included bruising or localized pain at the needle site.

Other adverse events

Other adverse events
Measure
Usual Care
n=47 participants at risk
Participants in the usual care group did not receive any additional treatment as part of the study. They were instructed to continue receiving any care recommended to them by their PCP or Long COVID Clinician.
Acupuncture
n=46 participants at risk
Participants in the Acupuncture group were asked to attend 8 weekly acupuncture sessions. Each session took place at a central primary care clinic. The visits lasted 1 hour and included a brief assessment, needle insertion at selected body and ear acupoints while the participant lay supine. After removing the needles, up to 10 Pyonex press tags (shallow needles) were applied to specific points, and participants were instructed to keep them in place for at least 3 days.
Skin and subcutaneous tissue disorders
Bruising at the needle site
0.00%
0/47 • From enrollment until the end of follow-up (week 20)
For this study, a serious adverse event was anything requiring hospitalization, an ED visit, or death. None of the SAEs were related to the study. Adverse events included bruising or localized pain at the needle site.
8.7%
4/46 • Number of events 4 • From enrollment until the end of follow-up (week 20)
For this study, a serious adverse event was anything requiring hospitalization, an ED visit, or death. None of the SAEs were related to the study. Adverse events included bruising or localized pain at the needle site.
Skin and subcutaneous tissue disorders
Localized pain at needle site
0.00%
0/47 • From enrollment until the end of follow-up (week 20)
For this study, a serious adverse event was anything requiring hospitalization, an ED visit, or death. None of the SAEs were related to the study. Adverse events included bruising or localized pain at the needle site.
10.9%
5/46 • Number of events 5 • From enrollment until the end of follow-up (week 20)
For this study, a serious adverse event was anything requiring hospitalization, an ED visit, or death. None of the SAEs were related to the study. Adverse events included bruising or localized pain at the needle site.

Additional Information

Nicole Gentile

University of Washington

Phone: 206-616-3961

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place